Sesamol

Catalog No.S3626 Batch:S362601

Print

Technical Data

Formula

C7H6O3

Molecular Weight 138.12 CAS No. 533-31-3
Solubility (25°C)* In vitro DMSO 27 mg/mL (195.48 mM)
Water 27 mg/mL (195.48 mM)
Ethanol 27 mg/mL (195.48 mM)
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description Sesamol (1,3-Benzodioxol-5-ol, 3,4-Methylenedioxyphenol), a natural organic compound, is regarded as a major antioxidant component in the oil with chemoprevention, antimutagenic, and antihepatotoxic activities. It induces apoptosis of cancer and cardiovascular cells.
In vitro

Sesamol treatment suppresses colony formation, elicits S phase arrest during cell cycle progression, and induces both intrinsic and extrinsic apoptotic pathway in vitro with a dose-dependent manner. Furthermore, sesamol treatment elicits mitochondrial dysfunction by inducing a loss of mitochondrial membrane potential. Impaired mitochondria and accumulated H2O2 production results in disturbance of redox-sensitive signaling including Akt and MAPKs pathways. Mitochondrial biogenesis is inhibited as suggested by the decline in expression of mitochondrial complex I subunit ND1, and the upstream AMPK/PGC1α signals. Importantly, sesamol inhibits mitophagy and autophagy through impeding the PI3K Class III/Belin-1 pathway. Autophagy stimulator rapamycin reverses sesamol-induced apoptosis and mitochondrial respiration disorders[1]. Sesamol increases the activity of caspase 8, 9, and 3/7, indicating that apoptotic cell death occurred through both extrinsic and intrinsic pathways. Sesamol causes the loss of mitochondrial transmembrane potential signifying intrinsic apoptosis induction in human lung adenocarcinoma (SK-LU-1) cells[2].

In vivo

Sesamol has potent anti-hepatoma activity in a xenograft nude mice model[1].

Protocol (from reference)

Cell Assay:

[1]

  • Cell lines

    HepG2 cells, BRL-3A cells

  • Concentrations

    0, 0.01, 0.05, 0.1, 0.2, 0.5 or 1 mM

  • Incubation Time

    24 h

  • Method

    The cytotoxicity of sesamol on HepG2 cells and BRL-3A cells is examined by using MTT assay. Briefly, cells in exponential growth are seeded into 96-well plates at a density of 1 × 105 cells/mL. The cells are then treated with sesamol at various doses (0, 0.01, 0.05, 0.1, 0.2, 0.5 or 1 mM). After 24 h, the supernatant is discarded and 100 μL FBS free medium is added. 100 μL of MTT is added in each well, and cells are further incubated for 4 h in the dark. After incubation, the medium is discarded, 100 μL of DMSO is added, and the optical density of each well is measured at 570 nm.

Animal Study:

[1]

  • Animal Models

    Balb/c nu/nu mice

  • Dosages

    100 mg/kg or 200 mg/kg

  • Administration

    i.p.

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.